资讯
The antibody drug reduced the risk of developing symptomatic Covid-19 infection by 81% compared with a placebo in people living with someone infected by the new coronavirus, a study found.
People taking immunosuppressive drugs to prevent organ transplant rejection or to treat inflammatory or autoimmune diseases do not fare worse than others on average when they are hospitalized with ...
A monoclonal-antibody drug reduced hospitalizations or death from Covid-19 by 85% compared with a placebo in a clinical trial, said Vir Biotechnology and GlaxoSmithKline, the drug’s developers.
The SCORPIO-PEP trial found the drug ensitrelvir, already approved in Japan to treat people with mild to moderate COVID-19, may protect against the illness. In the study, uninfected people who began ...
The study looked at a variety of literature for drug therapies for COVID-19 -- including hydroxychloroquine, remedesivier, tocilizumab and steroids -- on PubMed.
To study the efficacy of other therapeutic drugs, such as immunomodulators and monoclonal antibodies explicitly targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the trial is ...
Drugs typically used to treat rheumatoid arthritis by reducing inflammation were found in a new study to help critically ill Covid-19 patients in intensive care units.
Remdesivir has “little or no effect on mortality” for patients hospitalized with coronavirus and it doesn’t seem to help Covid-19 patients recover any faster, either.
Potential COVID-19 drug is successful in lab study. ScienceDaily. Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2021 / 01 / 210119194322.htm. Rush University Medical Center.
The treatment of choice for a while. In 2020, then-President Donald Trump said he had been taking hydroxychloroquine to prevent a COVID-19 infection, despite warnings by the U.S. Food and Drug ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果